DOP2016000286A - Compuesto heterocíclico que contiene nitrógeno - Google Patents
Compuesto heterocíclico que contiene nitrógenoInfo
- Publication number
- DOP2016000286A DOP2016000286A DO2016000286A DO2016000286A DOP2016000286A DO P2016000286 A DOP2016000286 A DO P2016000286A DO 2016000286 A DO2016000286 A DO 2016000286A DO 2016000286 A DO2016000286 A DO 2016000286A DO P2016000286 A DOP2016000286 A DO P2016000286A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compound containing
- heterocyclic compound
- containing nitrogen
- dementia
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención proporciona un compuesto que tiene una actividad del receptor colinérgico muscarínico M1 del modulador alostérico positivo y útil como un agente para la profilaxis o el tratamiento de la enfermedad de Alzheimer, la esquizofrenia, el dolor, el trastorno del sueño, la demencia de la enfermedad de Parkinson o la demencia con cuerpos de Lewy, y similares. La presente invención se refiere a un compuesto representado por la fórmula (I) o una sal del mismo. en la que cada símbolo está de acuerdo con lo descripto en la memoria descriptiva, o una sal del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014089585 | 2014-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2016000286A true DOP2016000286A (es) | 2017-02-15 |
Family
ID=53276227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2016000286A DOP2016000286A (es) | 2014-04-23 | 2016-10-20 | Compuesto heterocíclico que contiene nitrógeno |
Country Status (36)
Country | Link |
---|---|
US (16) | US9315458B2 (es) |
EP (1) | EP3134386B1 (es) |
JP (1) | JP6517239B2 (es) |
KR (1) | KR102349237B1 (es) |
CN (1) | CN106536508B (es) |
AR (1) | AR100154A1 (es) |
AU (1) | AU2015250610B2 (es) |
BR (1) | BR112016024472B1 (es) |
CA (1) | CA2946519C (es) |
CL (1) | CL2016002661A1 (es) |
CR (1) | CR20160544A (es) |
CY (1) | CY1123569T1 (es) |
DK (1) | DK3134386T3 (es) |
DO (1) | DOP2016000286A (es) |
EA (1) | EA030373B1 (es) |
EC (1) | ECSP16090152A (es) |
ES (1) | ES2811088T3 (es) |
HR (1) | HRP20201171T1 (es) |
HU (1) | HUE050543T2 (es) |
IL (1) | IL248393B (es) |
LT (1) | LT3134386T (es) |
MX (1) | MX2016013810A (es) |
MY (1) | MY195742A (es) |
NZ (1) | NZ725921A (es) |
PE (1) | PE20161400A1 (es) |
PH (1) | PH12016502095A1 (es) |
PL (1) | PL3134386T3 (es) |
PT (1) | PT3134386T (es) |
RS (1) | RS60524B1 (es) |
SG (1) | SG11201608785PA (es) |
SI (1) | SI3134386T1 (es) |
TN (1) | TN2016000455A1 (es) |
TW (1) | TWI664165B (es) |
UA (1) | UA122391C2 (es) |
UY (1) | UY36091A (es) |
WO (1) | WO2015163485A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2755827T3 (es) | 2013-03-15 | 2020-04-23 | Incyte Holdings Corp | Heterciclos tricíclicos como inhibidores de proteína BET |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
PT3134386T (pt) | 2014-04-23 | 2020-08-25 | Takeda Pharmaceuticals Co | Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer |
UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
WO2015174534A1 (ja) | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
JP6571077B2 (ja) | 2014-06-13 | 2019-09-04 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
PE20180500A1 (es) | 2015-06-26 | 2018-03-09 | Takeda Pharmaceuticals Co | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 |
US10548899B2 (en) | 2015-10-20 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
EP3428150B1 (en) | 2016-03-11 | 2023-07-12 | Takeda Pharmaceutical Company Limited | Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity |
CN114366748A (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
WO2018005249A1 (en) * | 2016-06-28 | 2018-01-04 | Merck Sharp & Dohme Corp. | Benzoisoquinolinone m1 receptor positive allosteric modulators |
CN110753689B (zh) * | 2017-02-28 | 2024-01-26 | 武田药品工业株式会社 | 用于生产杂环化合物的方法 |
JP7145875B2 (ja) | 2017-04-18 | 2022-10-03 | 武田薬品工業株式会社 | アセチルコリン受容体のモジュレーターとして有用な複素環化合物 |
US20200182850A1 (en) | 2017-05-19 | 2020-06-11 | Takeda Pharmaceutical Company Limited | Screening method |
US10945771B2 (en) | 2017-06-09 | 2021-03-16 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor |
BR112019026096A2 (pt) | 2017-06-20 | 2020-07-07 | Takeda Pharmaceutical Company Limited | composto, medicamento, métodos para modulação alostérica positiva do receptor muscarínico colinérgico m1 e para a profilaxia ou o tratamento de constipação, e, uso do composto |
HUE063823T2 (hu) | 2017-06-20 | 2024-02-28 | Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként | |
WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
WO2019000236A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
JP2020158392A (ja) * | 2017-07-25 | 2020-10-01 | Agc株式会社 | フルオロフェノール誘導体の製造方法及び新規なフルオロ化合物 |
SG11202004580WA (en) * | 2017-11-23 | 2020-06-29 | Suven Life Sciences Ltd | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators |
US20220041581A1 (en) | 2018-09-28 | 2022-02-10 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
KR20210068025A (ko) | 2018-09-28 | 2021-06-08 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
US11970483B2 (en) | 2018-09-28 | 2024-04-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2020139372A1 (en) * | 2018-12-28 | 2020-07-02 | Shui Yin Lo | Method for detection treatment and prevention of neurological development disorders |
AU2021315961A1 (en) * | 2020-07-29 | 2023-02-16 | Vivozon Inc. | Dual regulator for MGLUR5 and 5-HT2A receptors and use thereof |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4416647Y1 (es) | 1965-05-26 | 1969-07-18 | ||
JPS60172704A (ja) | 1984-02-14 | 1985-09-06 | Mitsuwa Seiki Co Ltd | 流体アクチユエ−タの制御方法 |
JP2699511B2 (ja) | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
TW219935B (es) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
JPH06220044A (ja) * | 1991-12-25 | 1994-08-09 | Mitsubishi Kasei Corp | ベンズアミド誘導体 |
GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
AU5716898A (en) | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
WO2002003684A2 (en) | 2000-06-30 | 2002-01-10 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
EP1372620A2 (en) | 2001-03-15 | 2004-01-02 | Saegis Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
WO2002081446A1 (en) | 2001-04-06 | 2002-10-17 | Daewoong Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof |
WO2002081447A1 (en) | 2001-04-06 | 2002-10-17 | Daewoong Pharmaceutical Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof |
US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
DE10137163A1 (de) | 2001-07-30 | 2003-02-13 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
NZ542690A (en) | 2003-03-28 | 2009-04-30 | Acadia Pharm Inc | Muscarinic M1 receptor agonists for pain management |
US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
JP2008536866A (ja) | 2005-04-15 | 2008-09-11 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | アミン作動性医薬組成物および方法 |
US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
TW200806625A (en) | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
US8143284B2 (en) | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
WO2008113072A2 (en) | 2007-03-15 | 2008-09-18 | Board Of Regents, The University Of Texas System | Gpcr enhanced neuroprotection to treat brain injury |
EP2200610B1 (en) | 2007-09-21 | 2018-01-10 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
CA2700332A1 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
EP2215074B1 (en) | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
EP2398324B1 (en) | 2009-02-23 | 2014-09-03 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
SG174220A1 (en) | 2009-03-05 | 2011-10-28 | Mithridion Inc | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
ES2759751T3 (es) | 2009-07-14 | 2020-05-12 | Nerviano Medical Sciences Srl | 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas |
HUE044653T2 (hu) | 2009-07-22 | 2019-11-28 | PureTech Health LLC | Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
ES2842399T3 (es) * | 2009-12-22 | 2021-07-14 | Vertex Pharma | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa |
US8314120B2 (en) * | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
WO2012149524A1 (en) | 2011-04-29 | 2012-11-01 | The University Of Toledo | Muscarinic agonists as enhancers of working memory and cognitive flexibility |
US9206200B2 (en) | 2011-05-17 | 2015-12-08 | Merck Sharp & Dohme Corp. | N-linked lactam M1 receptor positive allosteric mogulators |
WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
PT2770997T (pt) | 2011-10-28 | 2016-12-01 | Univ Vanderbilt | Análogos de 2-(4-heterociclilbenzil)isoindolin-1-ona substituídos como moduladores alostéricos positivos do receptor m1 de acetilcolina muscarínico |
EP2821401B1 (en) | 2012-03-02 | 2020-09-09 | Takeda Pharmaceutical Company Limited | Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor |
US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
EP3049391B1 (en) | 2013-09-27 | 2018-12-26 | F.Hoffmann-La Roche Ag | Indole and indazole derivatives |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
PT3134386T (pt) * | 2014-04-23 | 2020-08-25 | Takeda Pharmaceuticals Co | Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer |
US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
EP3562477A4 (en) | 2016-12-29 | 2020-11-18 | Synnerva Ltd. | PROCEDURES AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS |
-
2015
- 2015-04-22 PT PT157263625T patent/PT3134386T/pt unknown
- 2015-04-22 US US14/693,342 patent/US9315458B2/en active Active
- 2015-04-22 JP JP2016564111A patent/JP6517239B2/ja active Active
- 2015-04-22 US US15/306,012 patent/US9868725B2/en active Active
- 2015-04-22 EP EP15726362.5A patent/EP3134386B1/en active Active
- 2015-04-22 EA EA201692132A patent/EA030373B1/ru not_active IP Right Cessation
- 2015-04-22 BR BR112016024472-9A patent/BR112016024472B1/pt active IP Right Grant
- 2015-04-22 UA UAA201611867A patent/UA122391C2/uk unknown
- 2015-04-22 NZ NZ725921A patent/NZ725921A/en unknown
- 2015-04-22 TW TW104112837A patent/TWI664165B/zh active
- 2015-04-22 RS RS20200816A patent/RS60524B1/sr unknown
- 2015-04-22 SI SI201531316T patent/SI3134386T1/sl unknown
- 2015-04-22 CN CN201580034130.XA patent/CN106536508B/zh active Active
- 2015-04-22 TN TN2016000455A patent/TN2016000455A1/en unknown
- 2015-04-22 CR CR20160544A patent/CR20160544A/es unknown
- 2015-04-22 MX MX2016013810A patent/MX2016013810A/es active IP Right Grant
- 2015-04-22 HU HUE15726362A patent/HUE050543T2/hu unknown
- 2015-04-22 PL PL15726362T patent/PL3134386T3/pl unknown
- 2015-04-22 PE PE2016002118A patent/PE20161400A1/es unknown
- 2015-04-22 UY UY0001036091A patent/UY36091A/es not_active Application Discontinuation
- 2015-04-22 ES ES15726362T patent/ES2811088T3/es active Active
- 2015-04-22 SG SG11201608785PA patent/SG11201608785PA/en unknown
- 2015-04-22 AR ARP150101206A patent/AR100154A1/es active IP Right Grant
- 2015-04-22 KR KR1020167032435A patent/KR102349237B1/ko active IP Right Grant
- 2015-04-22 AU AU2015250610A patent/AU2015250610B2/en active Active
- 2015-04-22 WO PCT/JP2015/062912 patent/WO2015163485A1/en active Application Filing
- 2015-04-22 LT LTEP15726362.5T patent/LT3134386T/lt unknown
- 2015-04-22 CA CA2946519A patent/CA2946519C/en active Active
- 2015-04-22 DK DK15726362.5T patent/DK3134386T3/da active
- 2015-04-22 MY MYPI2016703862A patent/MY195742A/en unknown
-
2016
- 2016-02-02 US US15/013,675 patent/US9518042B2/en active Active
- 2016-02-02 US US15/013,625 patent/US9499516B2/en active Active
- 2016-10-12 US US15/291,769 patent/US9675597B2/en active Active
- 2016-10-19 CL CL2016002661A patent/CL2016002661A1/es unknown
- 2016-10-19 IL IL24839316A patent/IL248393B/en active IP Right Grant
- 2016-10-20 DO DO2016000286A patent/DOP2016000286A/es unknown
- 2016-10-20 PH PH12016502095A patent/PH12016502095A1/en unknown
- 2016-11-23 EC ECIEPI201690152A patent/ECSP16090152A/es unknown
- 2016-12-22 US US15/388,887 patent/US9662316B2/en active Active
- 2016-12-22 US US15/388,834 patent/US9655881B2/en active Active
-
2017
- 2017-04-14 US US15/488,002 patent/US9775827B2/en active Active
- 2017-05-30 US US15/608,557 patent/US9789083B2/en active Active
- 2017-05-30 US US15/608,565 patent/US9789084B2/en active Active
- 2017-08-24 US US15/685,800 patent/US20180000780A1/en not_active Abandoned
- 2017-12-04 US US15/830,634 patent/US10457670B2/en active Active
-
2018
- 2018-12-04 US US16/209,349 patent/US10865200B2/en active Active
-
2020
- 2020-07-27 HR HRP20201171TT patent/HRP20201171T1/hr unknown
- 2020-07-27 CY CY20201100688T patent/CY1123569T1/el unknown
- 2020-09-30 US US17/038,917 patent/US20210009572A1/en not_active Abandoned
-
2022
- 2022-07-25 US US17/872,680 patent/US20220411413A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/504,741 patent/US20240109874A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
DOP2017000309A (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico | |
CL2018000429A1 (es) | Moduladores de la expresión de kras | |
BR112017010354A2 (pt) | compostos de triazolopirimidina e usos dos mesmos | |
CL2017000075A1 (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
ECSP17028463A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 | |
UY36071A (es) | Compuesto de ciclopropanamina y sus usos | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
CO7141410A2 (es) | Compuesto heterocíclico nitrogenado | |
ECSP17035415A (es) | 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1 | |
PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
ECSP17028459A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
UY36263A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso | |
SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
CL2016002677A1 (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1. | |
CO2017004785A2 (es) | N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a | |
SV2017005527A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
ECSP18006622A (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico |